Alkaline phosphatase in metastatic castration-resistant prostate cancer: reassessment of an older biomarker

被引：59
|
作者：
Heinrich, Daniel [1 ]
Bruland, Oyvind [2 ]
Guise, Theresa A. [3 ]
Suzuki, Hiroyoshi [4 ]
Sartor, Oliver [5 ,6 ]
机构：
[1] Akershus Univ Hosp, Dept Oncol, Sykehusveien 25, N-1478 Lorenskog, Norway
[2] Oslo Univ Hosp, Dept Oncol, Norwegian Radium Hosp, Ullernchausseen 70, N-0379 Oslo, Norway
[3] Indiana Univ Sch Med, Dept Med, 980 W Walnut St,Walther Hall,R3,Room C130, Indianapolis, IN 46202 USA
[4] Toho Univ, Dept Urol, Sakura Med Ctr, 564-1 Shimazu, Sakura, Chiba 2858741, Japan
[5] Tulane Canc Ctr, Dept Med, 1430 Tulane Ave,SL-42, New Orleans, LA 70112 USA
[6] Tulane Canc Ctr, Dept Urol, 1430 Tulane Ave,SL-42, New Orleans, LA 70112 USA
来源：
FUTURE ONCOLOGY | 2018年 / 14卷 / 24期
关键词：
alkaline phosphatase; biomarker; bone metastases; castration-resistant prostate cancer; mechanism of action; prognostic marker; survival; BONE METASTASES; SIPULEUCEL-T; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; PROGNOSTIC MODEL; DOUBLE-BLIND; 1ST-LINE CHEMOTHERAPY; RADIUM-223; DICHLORIDE; EXPLORATORY ANALYSIS; SKELETAL METASTASES;
D O I：
10.2217/fon-2018-0087
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Since most patients with metastatic castration-resistant prostate cancer (mCRPC) have bone metastases, it is important to understand the potential impact of therapies on prognostic biomarkers, such as ALP. Clinical studies involving mCRPC life-prolonging agents (i.e., sipuleucel-T, abiraterone, enzalutamide, docetaxel, cabazitaxel, and radium-223) have shown that baseline ALP level is prognostic for overall survival, and may be a better prognostic marker for overall survival than prostate-specific antigen in patients with bone-dominant mCRPC. Mechanism of action differences between therapies may partly explain ALP dynamics during treatment. ALP changes can be interpreted within the context of other parameters while monitoring disease activity to better understand the underlying pathology. This review evaluates the current role of ALP in mCRPC.
引用
收藏
页码：2543 / 2556
页数：14
相关论文
共 50 条
  • [21] Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
    Galletti, Giuseppe
    Leach, Benjamin I.
    Lam, Linda
    Tagawa, Scott T.
    CANCER TREATMENT REVIEWS, 2017, 57 : 16 - 27
  • [22] Patient-reported outcomes in metastatic castration-resistant prostate cancer
    Fallowfield, Lesley
    Payne, Heather
    Jenkins, Valerie
    NATURE REVIEWS CLINICAL ONCOLOGY, 2016, 13 (10) : 643 - 650
  • [23] Treatment of metastatic, castration-resistant prostate cancer
    von Amsberg, G.
    Merseburger, A. S.
    UROLOGE, 2020, 59 (06): : 673 - 679
  • [24] Cabazitaxel in metastatic castration-resistant prostate cancer
    Yap, Timothy A.
    Pezaro, Carmel J.
    de Bono, Johann S.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (09) : 1129 - 1136
  • [25] Radium-223 in patients with metastatic castration-resistant prostate cancer: Efficacy and safety in clinical practice
    Prelaj, Arsela
    Rebuzzi, Sara Elena
    Buzzacchino, Federica
    Pozzi, Chiara
    Ferrara, Carla
    Frantellizzi, Viviana
    Follacchio, Giulia Anna
    Civitelli, Liana
    De Vincentis, Giuseppe
    Tomao, Silverio
    Bianco, Vincenzo
    ONCOLOGY LETTERS, 2019, 17 (02) : 1467 - 1476
  • [26] Metastatic castration-resistant prostate cancer
    Henriques, Vanessa
    Wenzel, Mike
    Demes, Melanie-Christin
    Koellermann, Jens
    PATHOLOGE, 2021, 42 (04): : 431 - 438
  • [27] Pembrolizumab for metastatic castration-resistant prostate cancer: trials and tribulations
    Tsai, Alexander K.
    Kagalwalla, Sana
    Langer, Jenna
    Le-Kumar, Thuy
    Le-Kumar, Vikas
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2024, 24 (1-2) : 51 - 62
  • [28] Prognostic, predictive and potential surrogate markers in castration-resistant prostate cancer
    Aziz, Atiqullah
    Kempkensteffen, Carsten
    May, Matthias
    Lebentrau, Steffen
    Burger, Maximilian
    Chun, Felix K-H
    Brookman-May, Sabine
    EXPERT REVIEW OF ANTICANCER THERAPY, 2015, 15 (06) : 649 - 666
  • [29] Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
    Nilsson, Sten
    CURRENT ONCOLOGY REPORTS, 2016, 18 (02) : 1 - 12
  • [30] Chromogranin A: a useful biomarker in castration-resistant prostate cancer
    Ploussard, Guillaume
    Rozet, Francois
    Roubaud, Guilhem
    Stanbury, Trevor
    Sargos, Paul
    Roupret, Morgan
    WORLD JOURNAL OF UROLOGY, 2023, 41 (02) : 361 - 369
12345